L
Laury Poulain
Researcher at French Institute of Health and Medical Research
Publications - 15
Citations - 934
Laury Poulain is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 9, co-authored 11 publications receiving 732 citations. Previous affiliations of Laury Poulain include Paris Descartes University & Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Nathalie Jacque,Anne Marie Ronchetti,Clément Larrue,Clément Larrue,Godelieve Meunier,Rudy Birsen,Lise Willems,Estelle Saland,Estelle Saland,Justine Decroocq,Thiago Trovati Maciel,Mireille Lambert,Laury Poulain,Pierre Sujobert,Laure Joseph,Nicolas Chapuis,Nicolas Chapuis,Catherine Lacombe,Catherine Lacombe,Ivan C. Moura,Susan Demo,Jean-Emmanuel Sarry,Jean-Emmanuel Sarry,Christian Recher,Christian Recher,Patrick Mayeux,Patrick Mayeux,Jerome Tamburini,Didier Bouscary +28 more
TL;DR: It is shown that glutamine levels control mitochondrial oxidative phosphorylation (OXPHOS) in acute myeloid leukemia (AML) cells and targeting glutamine addiction via GLS1 inhibition offers a potential novel therapeutic strategy for AML.
Journal ArticleDOI
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
Lise Willems,Lise Willems,Nathalie Jacque,Arnaud Jacquel,Nathalie Neveux,Thiago Trovati Maciel,Mireille Lambert,Alain Schmitt,Laury Poulain,Alexa S. Green,Madalina Uzunov,Olivier Kosmider,Olivier Kosmider,Isabelle Radford-Weiss,Ivan C. Moura,Patrick Auberger,Norbert Ifrah,Valérie Bardet,Valérie Bardet,Nicolas Chapuis,Nicolas Chapuis,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Jerome Tamburini,Jerome Tamburini,Didier Bouscary,Didier Bouscary +28 more
TL;DR: It is shown that glutamine removal inhibits mTORC1 and induces apoptosis in AML cells, and that l-ases upregulate glutamine synthase expression in leukemic cells and that a GS knockdown enhances l-ase-induced apoptotic response in someAML cells.
Journal ArticleDOI
Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia
Pierre Sujobert,Laury Poulain,Etienne Paubelle,Florence Zylbersztejn,Adrien Grenier,Mireille Lambert,Elizabeth C. Townsend,Jean-Marie Brusq,Edwige Nicodeme,Justine Decrooqc,Ina Nepstad,Alexa S. Green,Johanna Mondesir,Nathalie Jacque,Alexandra N. Christodoulou,Tiffany DeSouza,Olivier Hermine,Marc Foretz,Benoit Viollet,Catherine Lacombe,Patrick Mayeux,David M. Weinstock,Ivan C. Moura,Didier Bouscary,Jerome Tamburini +24 more
TL;DR: It is reported that the specific AMPK agonist GSK621 selectively kills acute myeloid leukemia (AML) cells but spares normal hematopoietic progenitors, which results from a unique synthetic lethal interaction involving concurrent activation of AMPK and mTORC1.
Journal ArticleDOI
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells
Laury Poulain,Pierre Sujobert,Florence Zylbersztejn,Florence Zylbersztejn,Sylvain Barreau,Lucille Stuani,Lucille Stuani,Mireille Lambert,Tony Lionel Palama,Virginie Chesnais,Rudy Birsen,François Vergez,François Vergez,Thomas Farge,Thomas Farge,C Chenevier-Gobeaux,Marine Fraisse,Marine Fraisse,Frédéric Bouillaud,Frédéric Bouillaud,Frédéric Bouillaud,Christelle Debeissat,Olivier Herault,Christian Recher,Christian Recher,Catherine Lacombe,Michaela Fontenay,Patrick Mayeux,Thiago Trovati Maciel,Thiago Trovati Maciel,J-C Portais,J-E Sarry,J-E Sarry,Jerome Tamburini,Didier Bouscary,Nicolas Chapuis +35 more
TL;DR: It is demonstrated that high mTORC1 activity creates a specific vulnerability to G6PD inhibition that may work as a new AML therapy, and the PPP using the G6 PD inhibitor 6-aminonicotinamide induces in vitro and in vivo cytotoxicity against AML cells and synergistically sensitizes leukemic cells to chemotherapy.
Journal ArticleDOI
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
Alexa S. Green,Thiago Trovati Maciel,Chae Yin,Fetta Mazed,Fetta Mazed,Elizabeth C. Townsend,Sylvain Pilorge,Mireille Lambert,Mireille Lambert,Etienne Paubelle,Arnaud Jacquel,Florence Zylbersztejn,Justine Decroocq,Laury Poulain,Laury Poulain,Pierre Sujobert,Pierre Sujobert,Nathalie Jacque,Nathalie Jacque,Kevin Adam,Kevin Adam,Jason C. C. So,Olivier Kosmider,Olivier Kosmider,Patrick Auberger,Olivier Hermine,David M. Weinstock,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Gary J. Vanasse,Anskar Y.H. Leung,Ivan C. Moura,Didier Bouscary,Didier Bouscary,Jerome Tamburini,Jerome Tamburini +37 more
TL;DR: It is found that Pim kinases governFLT3-ITD signaling and that their pharmacological or genetic inhibition restores cell sensitivity to FLT3 inhibitors, which represents a promising new avenue for AML therapy.